The Journal of Urology
Volume 181, Issue 1 , Pages 379-386, January 2009

GRC-6211, a New Oral Specific TRPV1 Antagonist, Decreases Bladder Overactivity and Noxious Bladder Input in Cystitis Animal Models

  • Ana Charrua

      Affiliations

    • Universidade do Porto, Porto, Portugal
  • ,
  • Célia D. Cruz

      Affiliations

    • Universidade do Porto, Porto, Portugal
  • ,
  • Shridhar Narayanan

      Affiliations

    • Department of Biological Research, Glenmark Pharmaceuticals, Ltd., Navi Mumbai, India
    • Financial interest and/or other relationship with Glenmark Pharmaceutical.
  • ,
  • Laxmikant Gharat

      Affiliations

    • Department of Discovery Chemistry, Glenmark Pharmaceuticals, Ltd., Navi Mumbai, India
    • Financial interest and/or other relationship with Glenmark Pharmaceutical.
  • ,
  • Srinivas Gullapalli

      Affiliations

    • Department of Biological Research, Glenmark Pharmaceuticals, Ltd., Navi Mumbai, India
    • Financial interest and/or other relationship with Glenmark Pharmaceutical.
  • ,
  • Francisco Cruz

      Affiliations

    • Institute of Histology and Embryology, Faculty of Medicine and Instituto de Biologia Molecular e Celular, Porto, Portugal
    • Department of Urology, Hospital de São João, Porto, Portugal
  • ,
  • António Avelino

      Affiliations

    • Universidade do Porto, Porto, Portugal
    • Corresponding Author InformationCorrespondence: Institute of Histology and Embryology, Faculty of Medicine of Porto, Universidade do Porto, Porto, Portugal (FAX: 225513655)

Received 2 April 2008 published online 17 November 2008.

Purpose

We evaluated the effects of GRC-6211, an orally active TRPV1 antagonist, on the function and noxious input of naïve and inflamed bladders.

Materials and Methods

In urethane (Sigma®) anesthetized rats 0.5 ml GRC-6211 (0.001, 0.01, 0.1 and 1 mg/kg weight) or its vehicle (0.5% methylcellulose) were administered through a duodenal catheter and cystometry was done during infusion of saline, 100 μM capsaicin or 0.5% acetic acid (Merck, Feltham, United Kingdom). Cystometry was also performed in WT and TRPV1 knockout mice treated with 1 mg/kg GRC-6211. Cystometry was done in rats inflamed with lipopolysaccharide after receiving 0.1 mg/kg GRC-6221 or vehicle. Spinal c-fos expression induced by 0.5% acetic acid was investigated after 0.1 mg/kg GRC-6211 or vehicle administration. TRPV1 immunoreactivity was evaluated in the bladder after GRC-6211 administration.

Results

The reflex activity of rat and WT mice naïve bladders was unchanged by GRC-6211 up to a dose of 0.1 mg/kg. At 1 mg/kg contractions were transiently suppressed in naïve rats and WT mice but not in TRPV1 knockout mice. GRC-6211 (0.1 mg/kg) completely prevented capsaicin induced irritation, while the 0.001, 0.01 or 0.1 mg/kg dose decreased the mean ± SD frequency of bladder contractions during acetic acid infusion from 1.5 ± 0.3 to 1.35 ± 0.35 (not significant), 0.9 ± 0.2 (p <0.05) and 0.8 ± 0.2 (p <0.05), respectively. Lipopolysaccharide inflamed rats had 1.4 ± 0.4 and 0.8 ± 0.1 contractions per minute after vehicle and GRC-6211, respectively (p <0.05). The c-fos expression induced by acetic acid was decreased by GRC-6211 (85.5 ± 19.1 to 46.7 ± 9.4, p <0.05). GRC-6211 did not change bladder TRPV1 immunoreactivity.

Conclusions

GRC-6211 counteracts the bladder hyperactivity and noxious input induced by cystitis. At high doses it suppresses normal bladder activity by a TRPV1 dependent mechanism. TRPV1 antagonists might be useful for cystitis.

Key Words: urinary bladder, Trpv1 protein, rat, cystitis, inflammation, pain

Abbreviations and Acronyms: KO, knockout, LPS, lipopolysaccharide, TRPV1, transient receptor potential vanilloid subfamily 1

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Study was performed according to the European Communities Council Directive of 24 November 1986 (86/609/EEC).

 Supported by POCI/SAU-NEU/55983/2004 from FCT, Portugal and Glenmark Pharmaceuticals, Ltd., India.

PII: S0022-5347(08)02413-0

doi:10.1016/j.juro.2008.08.121

The Journal of Urology
Volume 181, Issue 1 , Pages 379-386, January 2009